StockData
Curanex Pharmaceuticals Inc logo

Curanex Pharmaceuticals Inc (CURX) stock

CURXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$4.70+0.07 (+1.40%)

Close on Nov 17, 2026Market cap $7.37MP/E –Yield –

Curanex Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Curanex Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $9.11M. For fiscal 2025 it was $2.99M.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.99M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.95M+188.2%
Q2 FY2026Jun 30, 2026$2.59M–
Q1 FY2026Mar 31, 2026$2.26M–
Q4 FY2025Dec 31, 2025$2.31M–
Q3 FY2025Sep 30, 2025$677.47K–

More Curanex Pharmaceuticals figures

See a number that looks wrong?